Hims & Hers (NYSE: HIMS) CEO Andrew Dudum isn't interested in taking insurance onto his platform, and that shows how disruptive the company could be. This could be the next great growth stock if Dudum's plans to aggregate demand play out as hoped.
*Stock prices used were end-of-day prices of May 6, 2025. The video was published on May 7, 2025.
Should you invest $1,000 in Hims & Hers Health right now?
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $613,546!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $695,897!*
Now, it’s worth noting Stock Advisor’s total average return is 893% — a market-crushing outperformance compared to 162% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of May 5, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Travis Hoium has positions in Hims & Hers Health, Shopify, and Walt Disney. The Motley Fool has positions in and recommends Amazon, Meta Platforms, Netflix, Shopify, and Walt Disney. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
